
News|Articles|February 13, 2019
Yupelri for Chronic Obstructive Pulmonary Disease
Author(s)Drew Boxler
Advertisement
Yupelri (revefenacin, Mylan®)
Indications: Patients with chronic obstructive pulmonary disease
Dosage: One 175 mcg vial (3 mL) once daily.
Contraindications: hypersensitivity to revefenacin or any component of this product.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
TrumpRx Officially Launches, Introduces Drug Prices
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
As Immunization Schedules Change, Vaccine Confidence Among Patients Falters
4
Q&A: PBMs, Community Pharmacy’s Next Move Following PBM Reform Signing
5























